Stimulation of the endosomal TLR pathway enhances autophagy-induced cell death in radiotherapy of breast cancer

Genes and Genomics

Volumn 32, Issue 6, 2010, Pages 599-606

  Kang, Su Jin ^a   Tak, Ji Hye ^a   Cho, Jung Hyun ^a   Lee, Hyo Ji ^a   Jung, Yu Jin ^a  

^a Kangwon National University   (South Korea)

Author keywords

Autophagy; Imiquimod; MCF 7; Poly(I:C); Radiotherapy; Toll like receptor (TLR)

Indexed keywords

3 METHYLADENINE; GARDIQUIMOD; IMIQUIMOD; POLYINOSINIC POLYCYTIDYLIC ACID; RAPAMYCIN; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGY; BREAST CANCER; BREAST CANCER CELL LINE; CANCER CELL; CANCER RADIOTHERAPY; CELL DEATH; CELL GROWTH; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DRUG SYNTHESIS; ENDOSOME; GENE EXPRESSION; GROWTH RATE; HUMAN; HUMAN CELL; IN VITRO STUDY; MCF 7 CELL LINE; RADIATION EXPOSURE; SIGNAL TRANSDUCTION;

EID: 84905859552     PISSN: 19769571     EISSN: 20929293     Source Type: Journal    
DOI: 10.1007/s13258-010-0139-x     Document Type: Article

References (37)

1. Akira S (2006) TLR signaling. Curr. Top. Microbiol .Immunol. 311: 1-16.
2. Celis E (2007) Toll-like receptor ligands energize peptide vaccines through multiple paths. Cancer Res. 67: 7945-7947.
3. Choi SS, Chung E and Jung YJ (2010) Newly identified CpG ODNs, M5-30 and M6-395, stimulate mouse immune cells to secrete TNF-alpha and enhance Th1-mediated immunity. J. Microbiol. 48: 512-517.
4. Cormary C, Hiver E, Mariame B, Favre G and Tilkin-Mariame AF (2005) Coexpression of CD40L and CD70 by semiallogenic tumor cells induces anti-tumor immunity. Cancer Gene Ther. 12: 963-972.
5. Djavaheri-Mergny M, Maiuri MC and Kroemer G (2010) Cross talk between apoptosis and autophagy by caspase-mediated cleavage of Beclin 1. Oncogene 29: 1717-1719.
6. Dotti G (2009) Blocking PD-1 in cancer immunotherapy. Blood 114: 1457-1458.
7. Egen JG, Kuhns MS and Allison JP (2002) CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat. Immunol. 3: 611-618.
8. Elpek KG, Lacelle C, Singh NP, Yolcu ES and Shirwan H (2007) CD4+CD25+ T regulatory cells dominate multiple immune evasion mechanisms in early but not late phases of tumor development in a B cell lymphoma model. J. Immunol. 178: 6840-6848.
9. Flavell RA, Sanjabi S, Wrzesinski SH and Licona-Limon P (2010) The polarization of immune cells in the tumour environment by TGFbeta. Nat. Rev. Immunol. 10: 554-567.
10. Gyrd-Hansen M and Meier P (2010) IAPs: from caspase inhibitors to modulators of NF-kappaB, inflammation and cancer. Nat. Rev. Cancer 10: 561-574.
11. Hanada T, Noda NN, Satomi Y, Ichimura Y, Fujioka Y, Takao T, Inagaki F and Ohsumi Y (2007) The Atg12-Atg5 conjugate has a novel E3-like activity for protein lipidation in autophagy. J. Biol. Chem. 282: 37298-37302.
12. Huang B, Zhao J, Unkeless JC, Feng ZH and Xiong H (2008) TLR signaling by tumor and immune cells: a double-edged sword. Oncogene 27: 218-224.
13. Kabeya Y, Mizushima N, Ueno T, Yamamoto A, Kirisako T, Noda T, Kominami E, Ohsumi Y and Yoshimori T (2000) LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. Embo J. 19: 5720-5728.
14. Krieg AM (2007) Development of TLR9 agonists for cancer therapy. J. Clin. Invest. 117: 1184-1194.
15. Kumar B, Joshi J, Kumar A, Pandey BN, Hazra B and Mishra KP (2007) Radiosensitization by diospyrin diethylether in MCF-7 breast carcinoma cell line. Mol. Cell. Biochem. 304: 287-296.
16. Mathew R, Karantza-Wadsworth V and White E (2007) Role of autophagy in cancer. Nat. Rev. Cancer 7: 961-967.
17. Medzhitov R and Janeway C, Jr. (2000a) Innate immune recognition: mechanisms and pathways. Immunol. Rev. 173: 89-97.
18. Medzhitov R and Janeway C, Jr. (2000b) The Toll receptor family and microbial recognition. Trends Microbiol. 8: 452-456.
19. Melief CJ, Van Der Burg SH, Toes RE, Ossendorp F and Offringa R (2002) Effective therapeutic anticancer vaccines based on precision guiding of cytolytic T lymphocytes. Immunol. Rev. 188: 177-182.
20. Mizushima N and Yoshimori T (2007) How to interpret LC3 immunoblotting. Autophagy 3: 542-545.
21. Mougel L, Tarpin M, Albert P, Le Naour R, Devy J, Kaplan H, Venteo L, Carlier A and Madoulet C (2004) Three-dimensional culture and multidrug resistance: effects on immune reactivity of MCF-7 cells by monocytes. Anticancer Res. 24: 935-941.
22. Peng JC, Hyde C, Pai S, O'Sullivan BJ, Nielsen LK and Thomas R (2006) Monocyte-derived DC primed with TLR agonists secrete IL-12p70 in a CD40-dependent manner under hyperthermic conditions. J. Immunother. 29: 606-615.
23. Reed JC (2008) Bcl-2-family proteins and hematologic malignancies: history and future prospects. Blood 111: 3322-3330.
24. Roses RE, Xu M, Koski GK and Czerniecki BJ (2008) Radiation therapy and Toll-like receptor signaling: implications for the treatment of cancer. Oncogene 27: 200-207.
25. Schwartz MJ, Liu H, Hwang DH, Kawamoto H and Scherr DS (2009) Antitumor effects of an imidazoquinoline in renal cell carcinoma. Urology 73: 1156-1162.
26. Smits EL, Ponsaerts P, Berneman ZN and Van Tendeloo VF (2008) The use of TLR7 and TLR8 ligands for the enhancement of cancer immunotherapy. Oncologist 13: 859-875.
27. Suzuki N, Suzuki S and Yeh WC (2002) IRAK-4 as the central TIR signaling mediator in innate immunity. Trends Immunol. 23: 503-506.
28. Thompson JA, Dissanayake SK, Ksander BR, Knutson KL, Disis ML and Ostrand-Rosenberg S (2006) Tumor cells transduced with the MHC class II Transactivator and CD80 activate tumor-specific CD4+ T cells whether or not they are silenced for invariant chain. Cancer Res. 66: 1147-1154.
29. Tormo D, Checinska A, Alonso-Curbelo D, Perez-Guijarro E, Canon E, Riveiro-Falkenbach E, Calvo TG, Larribere L, Megias D, Mulero F et al. (2009) Targeted activation of innate immunity for therapeutic induction of autophagy and apoptosis in melanoma cells. Cancer Cell 16: 103-114.
30. Tse K and Horner AA (2007) Update on toll-like receptor-directed therapies for human disease. Ann. Rheum. Dis. 66 Suppl 3: iii77-80.
31. Vidal D, Matias-Guiu X and Alomar A (2004) Efficacy of imiquimod for the expression of Bcl-2, Ki67, p53 and basal cell carcinoma apoptosis. Br. J. Dermatol. 151: 656-662.
32. Wang R, Wang X, Li B, Lin F, Dong K, Gao P and Zhang HZ (2009) Tumor-specific adenovirus-mediated PUMA gene transfer using the survivin promoter enhances radiosensitivity of breast cancer cells in vitro and in vivo. Breast Cancer Res. Treat. 117: 45-54.
33. Wang T, Tamae D, LeBon T, Shively JE, Yen Y and Li JJ (2005) The role of peroxiredoxin II in radiation-resistant MCF-7 breast cancer cells. Cancer Res. 65: 10338-10346.
34. Watts C, West MA and Zaru R (2010) TLR signalling regulated antigen presentation in dendritic cells. Curr. Opin. Immunol. 22: 124-130.
35. Xie Z and Klionsky DJ (2007) Autophagosome formation: core machinery and adaptations. Nat. Cell Biol. 9: 1102-1109.
36. Yi JY, Jung YJ, Choi SS, Hwang J and Chung E (2009) Autophagy-mediated anti-tumoral activity of imiquimod in Caco-2 cells. Biochem. Biophys. Res. Commun. 386: 455-458.
37. Zois CE and Koukourakis MI (2009) Radiation-induced autophagy in normal and cancer cells: towards novel cytoprotection and radio- sensitization policies? Autophagy 5: 442-450.